Par Drugs and Chemicals Limited

NSEI:PAR Stok Raporu

Piyasa değeri: ₹3.5b

Par Drugs and Chemicals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Par Drugs and Chemicals yıllık ortalama 21.2% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.3% annual. Gelirler growing yılda ortalama 15.2% oranında artmaktadır. Par Drugs and Chemicals'in özkaynak karlılığı 18.9% ve net marjı 17.6%'dir.

Anahtar bilgiler

21.2%

Kazanç büyüme oranı

21.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi17.5%
Gelir büyüme oranı15.2%
Özkaynak getirisi18.9%
Net Marj17.6%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Oct 29
There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03
Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19
If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17
Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22
Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11
Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31
Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05
Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06
Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13
How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Gelir ve Gider Dağılımı

Par Drugs and Chemicals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NSEI:PAR Gelir, gider ve kazançlar (INR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 241,041183580
30 Jun 24953146560
31 Mar 24956145550
31 Dec 23973142530
30 Sep 23962127520
30 Jun 23952115510
31 Mar 23957113490
31 Dec 22933103460
30 Sep 22873106420
30 Jun 2282191420
31 Mar 2275192410
31 Dec 21692112410
30 Sep 21686112410
30 Jun 21631115400
31 Mar 21608116400
31 Dec 2057988380
30 Sep 2055083380
30 Jun 2055465400
31 Mar 2055848410
31 Dec 1953241380
30 Sep 1950620360
30 Jun 1948423360
31 Mar 1946325360
31 Mar 1842415350
31 Mar 1748818330
31 Mar 163334220

Kaliteli Kazançlar: PAR yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: PAR 'nin mevcut net kar marjları (17.6%) geçen yılın (13.2%) sinden daha yüksektir.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PAR şirketinin kazançları son 5 yılda yılda 21.2% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: PAR 'un son bir yıldaki kazanç büyümesi ( 44.2% ) 5 yıllık ortalamasını (yıllık 21.2% ) aşıyor.

Kazançlar vs. Sektör: PAR geçen yılki kazanç büyümesi ( 44.2% ) Pharmaceuticals sektörünün 20.5% değerini aştı.


Özkaynak Getirisi

Yüksek ROE: PAR 'nin Özsermaye Getirisi ( 18.9% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin